Background
==========

Oral administration is still the optimal route to administer medication, especially for chronic diseases which need long-term treatment, and intravenous administration is not readily accepted by patients. Oral administration is the simplest and most effective route of treatment \[[@b1-medscimonit-22-3737],[@b2-medscimonit-22-3737]\]; however, some oral drugs are poorly soluble, so oral bioavailability is very low, which limits its application. Therefore, increasing the dose and changing the internal structure has become essential in improving the low bioavailability \[[@b3-medscimonit-22-3737]--[@b5-medscimonit-22-3737]\].

Wogonin has a variety of pharmacologic effects and biological activities, including anti-cancer \[[@b6-medscimonit-22-3737]\], anti-viral \[[@b7-medscimonit-22-3737]\], anti-oxidative \[[@b8-medscimonit-22-3737]\], anti-inflammatory \[[@b9-medscimonit-22-3737]\], and anti-seizure \[[@b10-medscimonit-22-3737]\] effects. Moreover, wogonin is used as remedial treatment in traditional Chinese medicine for fever, cough, respiratory tract inflammation, and hypotension, which could relieve patient discomfort, provide individualized treatment, and ensure compliance. Previous studies have shown that wogonin has potential in the prevention and treatment of tumors \[[@b11-medscimonit-22-3737]--[@b13-medscimonit-22-3737]\].

After oral administration, absorption in the gastrointestinal tract and hepatic metabolism and intake are needed to ensure entry of the drug in the body; however, the water solubility of wogonin is very low, which limits its application. The intrinsic physicochemical properties and low chemical stability of wogonin limits its bioavailability and further research and development. Therefore, it is very important to improve water solubility \[[@b4-medscimonit-22-3737],[@b14-medscimonit-22-3737],[@b15-medscimonit-22-3737]\].

Improvement in solubility could promote drug absorption and curative effect. To improve the solubility and bioavailability of insoluble drugs, researchers have found a variety of processing technologies, such as micronization, solubilization, salt formation, use of surfactants, complex formation with polymers, and alterations in pH \[[@b3-medscimonit-22-3737],[@b4-medscimonit-22-3737],[@b16-medscimonit-22-3737]--[@b20-medscimonit-22-3737]\]. Among various approaches, solid dispersion (SD) technology is promising in the application of low solubility drugs because SD technology has a number of advantages, is easy to use, and is economical. Increased wettability and reduced homogeneous distribution of a small amount of drug in the solid state and increased the interfacial area \[[@b21-medscimonit-22-3737]--[@b23-medscimonit-22-3737]\]. Various hydrophilic carriers are often used in SD preparation, such as polyethylene glycol, polyvinylpyrrolidone (PVP), labrasol, and poloxamers, which are used to improve the dissolution rate and bioavailability of drugs with poor water solubility. In the preparation of SD, the solvent method can be applied in mass production \[[@b14-medscimonit-22-3737],[@b16-medscimonit-22-3737],[@b21-medscimonit-22-3737],[@b24-medscimonit-22-3737]--[@b26-medscimonit-22-3737]\].

To the best of our knowledge, there are no reports on the detection of wogonin in beagles using the LC-MS/MS method. According to the literature \[[@b27-medscimonit-22-3737]\], by using HPLC detection, the minimum quantitative lower limit reached only 20 ng/mL, and was detected only in blood collected 5 h after the treatment, which does not meet the biological sample detection method 3\~5 half-life. Therefore, in the current study the LC-MS/MS method was successfully used in the determination of wogonin in the blood of beagles \[[@b28-medscimonit-22-3737]\]. SD has been widely and successfully used in improving the solubility and bioavailability of insoluble drugs \[[@b16-medscimonit-22-3737],[@b26-medscimonit-22-3737],[@b29-medscimonit-22-3737],[@b30-medscimonit-22-3737]\]. To further explore the reasons for the low long-tern level of the parent drug in the body, experiments involving the administration of a wogonin arginine solution were carried out. The reason for the low bioavailability of Wogonin was investigated to provide a reference for the continued study on the dosage form and clinical use.

Material and Methods
====================

Materials
---------

Wogonin (purity \>99%) and the solution preparation (10 g/L, wogonin arginine) were purchased from Heyuan Con-source Medicine Technology Co., Ltd., China. PVP-K30 was ordered from Zhongmei Huadong Pharmaceutical Technology Co. Ltd. (Hangzhou, China) and β-glucuronidase was ordered from (Sigma, USA). HPLC-grade methanol was obtained from Merck (Darmstadt, Germany). Formic acid (DIMA, USA) was of HPLC-grade and acetic ether was commercially available and of analytical grade. Distilled water processed using the Millipore purifying system was used throughout this study.

Animals
-------

Six male beagle dogs, with the average weight of 8.2±0.4 kg were obtained from the Jia'an Animal Experimentation Breeding Center (Zhejiang, China). The animals were cared for according to the regulations of the Animal Committee at the constant temperature of 22±1°C, 12-h/12-h light-dark cycle and 10--15 air changes per h for the feeding room. The studies were approved by the Animal Ethics Committee of Anhui Medical University.

Analytical system
-----------------

The data analysis was done using the Finnigan TSQ Quantum Discovery MAX system with ESI interface and Xcalibur workstation software (Ver. 1.4) for data processing. Isocratic elution used a mobile phase of methanol-water containing 0.1% formic acid (70: 30) and the mobile phase was ultrasonicated first before being filtered through a 0.45-μm Millipore filter. Separation was carried out on a Phenomenex^®^ Luna C18(2) column (150×2.0 mm, 5 μm, Code No. 490902-2) with a C18 guard column (Phenomenex, USA). The treated supernatant was transferred to an autosampler vial, and 10 μL was injected into the column for analysis. The flow rate was 0.2 ml/min and all the analyses were performed at 40°C. The optimized MS parameters were selected as follows: Spray Voltage 4.5 kV; Capillary Temperature 320°C; Source CID -4V; Sheath Gas Pressure 35 Arb; Aux Gas Pressure 5 Arb; Collision Pressure 1.2. Multiple-reaction monitoring (MRM) used the transitions of the protonated molecules at m/z 285.0→270.0 for wogonin and 373.3→305.3 for finasteride with scan time of 0.5 s per transition.

Preparation of the physical mixture and SD
------------------------------------------

A specific amount of crude material and some of the carriers were completely crushed and mixed to form the physical mixture, and stored in a dry container for further analysis. SD was prepared using the solvent method. The crude wogonin material and carrier were prepared, weighed, and dissolved in a sufficient amount of anhydrous alcohol. According to the dilution method, the mixture was added to the excipients.

Characterization of SD
----------------------

### XRD analysis and detection

PVP K30, wogonin, the physical mixture, and SD were analyzed with X-ray diffraction analysis. The running conditions were as follows: Cu target; graphite monochromator monochromatic diffraction; tube voltage, 40 kV; and tube current, 40 mA.

### DSC analysis and detection

PVP K30, wogonin, the physical mixture, and SD were analyzed with DCS analysis. The running conditions were as follows: the empty crucible was used as a reference aluminum pool; another empty crucible was used as a sample pool; approximately 10-mg samples were added; the scanning speed was 5°C/min; and the scanning range was 53\~303°C.

Dissolution analysis
--------------------

*In vitro* dissolution studies were performed using a USP dissolution device. A specific amount of wogonin crude drug and accessories (PVP K30) was dissolved in anhydrous ethanol, mixed, ultrasonic-treated, and depression vaporized in a 60°C water bath. After the solvent was completely dry, it was put in a dry container, and vacuum dried for 24 h. The solid was gently scraped, smashed, filtered through 80 mesh, and stored in a dry container.

Study on pharmacokinetics and bioavailability
---------------------------------------------

Six male beagles were introduced and randomly divided into 3 groups. Three periodic cross tests were performed in 3 preparations. All dogs were fasting, but water was permitted 12 h before the experiments. In the first cycle, drug was injected in group I via the small saphenous vein of the hind leg or ear vein (5 mL/kg, injection within 1 min, and at a constant speed). Three milliliters of blood of the contralateral hind limb vein was obtained before the administration of drug and at 0, 5, 10, 20, 30, 45, and 60 min, and 1.5, 2, 3, 4, 5, 6, 8, and 12 h after administration. Drug was administered intragastrically (i.g.) to group II (wogonin crude drug \[15 mg/kg\], mixed with 0.5% sodium carboxymethyl cellulose sodium solution). Drug was administered intragastrically to group III (solid dispersion of wogonin \[5 mg/kg\], mixed with 0.5% sodium carboxymethyl cellulose sodium solution). We used 20 mL of cold water to rinse the stomach tube after intragastric administration. Blood samples from the hind limb vein were obtained before the administration and at 0, 5, 10, 20, 30, 45, and 60 min, and 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 h after administration, placed in the centrifuge tube, centrifuged at 4000 rpm for 10 min to isolate plasma, and stored at −20°C until analysis. After a washout period of 1 week, the next cycle of administration was carried out. The blood sampling time points were the same as with the first cycle.

Results
=======

Characterization of SD
----------------------

### XRD analysis

PVP K30, wogonin, the physical mixture, and SD were analyzed by X-ray diffraction. [Figure 1A](#f1-medscimonit-22-3737){ref-type="fig"} shows crude materials of wogonin has a characteristic crystallization peak under XRD with many crystal diffraction peaks evident. PVP K30 is a kind of amorphous material without characteristic peaks within the range of 5--50°C ([Figure 1B](#f1-medscimonit-22-3737){ref-type="fig"}). A physical mixture with PVP K30 can decrease the characteristic crystallization peak of wogonin to a certain extent ([Figure 1C](#f1-medscimonit-22-3737){ref-type="fig"}). The form of the drug and physical mixture have obvious differences. After the SD was made, the crystallization peak of wogonin completely disappeared ([Figure 1D](#f1-medscimonit-22-3737){ref-type="fig"}). We can conclude the wogonin exists in molecular states in supplementary material, which indicates that wogonin existed in an amorphic state in SD.

### DSC analysis

DSC is considered to be a modern and accurate technique used in solid dispersion analysis. [Figure 2A](#f2-medscimonit-22-3737){ref-type="fig"} shows that the crystallization peak of wogonin has a sensitive crystal endothermic peak at 193.58°C. In the wogonin-PVP K30 (1:5) physical mixture, the characteristic absorption peak of wogonin at 193.58°C disappeared ([Figure 2C](#f2-medscimonit-22-3737){ref-type="fig"}). There is a weak endothermic peak at 148.16°C, which is the result of wogonin endothermic peak forward due to the crystalline form change of wogonin caused by hydrogen bond formation between drug and carrier during the heating process. The characteristic melting peak of wogonin in wogonin-PVP K30 (1:5) SD complete obliteration is not totally absent. There was no obvious endothermic or exothermic peak in the entire process ([Figure 2B](#f2-medscimonit-22-3737){ref-type="fig"}), which means that there was no drug crystal co-precipitate and wogonin exists in an amorphous state dispersed in the carrier.

Solubility study *in vitro*
---------------------------

The study on solubility *in vitro* showed that the dissolution rate of the SD of wogonin was significantly increased compared with the physical mixture and the crude material. The study also showed that when the drug loading ratio of SD was 1:5, the percentage of drug dissolution was 10.2 times the physical mixture at 10 min. The percentage of drug accumulation dissolution rate was \>80%, which was 7 times more than with the physical mixture. It is generally well known that a drug in a solid dispersions system sometimes exists in an amorphous form. The amorphous form of a drug has a higher thermodynamic activity than its crystalline form, leading to rapid dissolution of the drug. The improved drug release rate could be attributed to the drug crystallinity reduction in the wogonin-loaded solid dispersions prepared by PVP K30. Dissolution rate improvement for PMs may be mostly related to the hydrophilic effect of PVP. This hydrophilic polymer can reduce the interfacial tension between wogonin and the release medium and provide greater dissolution rates.

Study on pharmacokinetics and bioavailability
---------------------------------------------

### Study on the bioavailability of 3 types of drug delivery methods

The 3 routes of medication administration were intravenous (arginine salt solution), gastric (crude drug), and gastric (SD). The main pharmacokinetic parameters were as follows: *C~max~* (2.5±1.1), (7.9±3.3), and (6838.7±1322.1) μg/L; *t~max~* (0.7±0.3) and (0.3±0.2) h for the former; and AUC~0-t~ (7.1±2.0), (21.0±3.2), and (629.7±111.8) μg·h/L. The difference in AUC was very large between the different drug delivery methods; the individual difference in t1/2z was large, but the average value of different methods was not statistically significant (P\>0.05), which indicates that the elimination of wogonin was similar in the different routes of administration. Intragastric administration of SD was absorbed faster in dogs than the crude drug. The *C~max~* increased nearly 10 times compared with crude drug after dose correction. Elimination half-life of the 2 preparations showed there is no significant difference (P\>0.05). However, *t~max~* of solution preparation was shortened. The concentration of wogonin in plasma by i.v. route declined sharply (over 1/6000) by 2 h after dose administration. The parent drug cannot be detected after 12 h and mean residence time (MRT) of i.g. administration was obviously prolonged compared to the i.v. route. A 3-session crossover study evaluated pharmacokinetic parameters. The results for 3 treatments are depicted in [Table 1](#t1-medscimonit-22-3737){ref-type="table"}, [Figures 3](#f3-medscimonit-22-3737){ref-type="fig"}, and [4](#f4-medscimonit-22-3737){ref-type="fig"}, which showed the mean plasma concentration-time profile in 6 beagles after the 3 types of experiments.

Absolute bioavailability was determined by dividing the dose-normalized area under the plasma concentration-time curve (AUC) resulting from i.g. administration by that from i.v. injection, which was expressed as (AUC~ig~)×(Dose~iv~)/(AUC~iv~)×(Dose~ig~) ×100%. Result differences between native drug and solution preparation were rather amazing. The absolute bioavailability of crude drug was very low (about 0.6%), while the absolute bioavailability of SD was increased by nearly 7 times that of crude drug (about 4%), as shown in [Table 2](#t2-medscimonit-22-3737){ref-type="table"}.

### Detection of the free type of Wogonin and its main metabolites (wogonin7-β-D-glucuronic (W-7-G) acid) after wogonin arginine solution agent gastric administration in beagles

To investigate the reasons for the low level of the drug in the body, further experiments were performed. Six beagles were used in the study on the absolute bioavailability of wogonin; 1 week later, the experiment was started. The drug was administered via the intragastric route (5 mg/kg); the blood collection time points were the same as the last experiment involving intragastric administration sustained for 36 h. Before the plasma sample treatment, 100 μl of β-glucuronidase was added to the blood sample \[[@b31-medscimonit-22-3737]\] (1000 units/ml of 50 mM NH~4~H~2~PO~4~ buffer solution \[pH 5.0\]), and vortexed in a 37°C thermostatic water bath for 24 h (60 rpm).

The concentration of free drug in the blood was also lower by solution irrigation administration in beagles. Similar to the SD irrigation, the concentration of drug increased rapidly, followed by a rapid decline after 1 h, maintained at a lower concentration (\<5 ng/mL), and sustained for approximately 24 h. The concentration of the wogonin7-β-D-glucuronic acid in blood was very high (\>100 times the concentration of free drugs), followed by a rapid decline that may be related to its rapid distribution to other tissues, and a sustained low concentration after 4 h (\<20 ng), but could still be detected after 36 h ([Figure 5](#f5-medscimonit-22-3737){ref-type="fig"}).

The total blood concentration of free-type wogonin and β-glucuronidase -enzymolyzed wogonin was analyzed with the non-compartment model by medical professional statistical software (DAS2.0). The pharmacokinetic parameters of the main drugs are shown in [Table 3](#t3-medscimonit-22-3737){ref-type="table"}. The free-type of wogonin in the blood was calculated, and the *C~max~* of the solution agent administered via the intragastric route to beagles was higher than SD (12.3±3.3 *vs.* 7.9±3.3 μg/L), MRT~(0-t)~ was comparatively shorter (3.39±1.25 *vs.* 5.3±3.0 h), and AUC ~(0-∞)~ was decreased (17.8±70.4 *vs.* 21.9±16.8 μg/L\*h). No significant differences were found in other pharmacokinetic parameters. The absolute bioavailability of crude drug was very low (approximately 0.6%), while the absolute bioavailability of SD was increased by nearly 7 times compared to the crude drug (only 4%).

The relative bioavailability of the SD of wogonin was increased by approximately 679.9% compared with crude drug. To investigate the reasons for the low bioavailability of wogonin, LC/MS^n^/DAD technology was used to analyze the plasma of beagles after drug administration. Glucose acid conjugates were confirmed as the main metabolite of wogonin and no other metabolite was found. Beagles were administered the salt solution of wogonin orally. The total concentration of the wogonin in the plasma of the free-type and the wogonin after hydrolysis was detected. The relative bioavailability of salt solution of wogonin was 81.3% compared with SD. The total wogonin after enzymolysis by β-glucuronidase was calculated. The *C~max~* was approximately 12 times greater than the free-type of wogonin. AUC~(0-∞)~ was \>30 times. MRT~(0-t)~ was significantly prolonged (8.38±3.14 *vs.* 3.39±1.25 h).

Discussion
==========

Wogonin, 5,7-dihydroxy-8-methoxyflavone ([Figure 6](#f6-medscimonit-22-3737){ref-type="fig"}), a major bioactive flavonoid aglycones isolated from the roots of *Scutellaria baicalensis,* was demonstrated to have many pharmacologic effects and biological activities, including anti-cancer \[[@b6-medscimonit-22-3737]\], anti-viral \[[@b7-medscimonit-22-3737]\], anti-oxidative \[[@b8-medscimonit-22-3737]\], anti-inflammatory \[[@b9-medscimonit-22-3737]\], and anti-seizure \[[@b10-medscimonit-22-3737]\] effects. However, the water solubility of wogonin is very low, which limits its use. To improve the solubility and bioavailability of wogonin, researchers have used many kinds of processing technologies. Among various approaches, solid dispersion (SD) technology is promising in the application of low-solubility drugs \[[@b21-medscimonit-22-3737]--[@b23-medscimonit-22-3737]\], and the SD loaded with wogonin has not been reported previously.

In this study, the SDs were characterized by XRD and DSC analysis and showed that wogonin existed in an amorphic state in solid dispersions (SDs). In PM with a mount of the polymer (1:5 ratio), no diffraction peaks were discovered due to the polymer dilution effect \[[@b32-medscimonit-22-3737],[@b33-medscimonit-22-3737]\]. The disappearance of characteristic peaks in all SDs suggested a significant decrease in wogonin crystallinity, demonstrating a drug amorphization or its solvation in the amorphous carriers \[[@b5-medscimonit-22-3737],[@b33-medscimonit-22-3737],[@b34-medscimonit-22-3737]\]. DSC analysis enables the quantitative detection of all processes in which energy is required or produced. It allows exploring the process of melting, crystallization, evaporation, phase equilibriums, absorption, dehydration, sublimation, and substance degradation \[[@b35-medscimonit-22-3737],[@b36-medscimonit-22-3737]\]. The lower intensity of the melting peak might be related to the dilution effect of polymer and, and the shift of the endothermic peak to lower temperature could be a result of dissolving wogonin in the melted PVP solution or the possible heat-induced interactions between the drug and polymer \[[@b37-medscimonit-22-3737]\]. The study on solubility *in vitro* showed that the dissolution rate of wogonin-loaded solid dispersions prepared by PVP K30 was significantly increased compared with the physical mixture and the crude material. In addition to these mechanisms, an improvement in the dissolution rate of SDs could also be attributed to the drug particle size reduction and decrease in the drug crystallinity during the preparation of SDs \[[@b23-medscimonit-22-3737],[@b33-medscimonit-22-3737],[@b35-medscimonit-22-3737]\]. The release rate enhancement could also be explained by the solubilizing and wetting effect of PVP K30 \[[@b33-medscimonit-22-3737],[@b36-medscimonit-22-3737]\]. Increasing drug wettability and solubility as well as deaggregation of the drug particles brought about by the polymer could be the reasons for enhanced drug release rate from the SDs \[[@b14-medscimonit-22-3737],[@b21-medscimonit-22-3737],[@b32-medscimonit-22-3737],[@b33-medscimonit-22-3737]\].

Until now, only limited date have been available on the pharmacokinetics of wogonin in rats. The HPLC method with the lower limit of quantitation (LLOQ) of 20 ng/mL lacked the sensitivity necessary for the pharmacokinetics study of wogonin \[[@b27-medscimonit-22-3737]\]. In this report, we validated a simple and rapid LC-MS/MS method as being accurate, precise, and robust for determination of wogonin in dog plasma. The main pharmacokinetic parameters were analyzed with the non-compartment model by medical professional statistical software (DAS2.0). The Vz of the 2 kinds of irrigation was much larger than the body fluid volume, which indicated that the drug concentration was distributed to a specific organ or tissue. The Vd of intravenous administration was small, which indicated that drug metabolism or excretion was faster by the intravenous administration and that prototype drug *in vivo* retention time is relatively short. To investigate the reasons for the low level of the drug in the body, further experiments were performed. In the current study, salt solution of wogonin was given to beagles by intragastric administration (5 mg/kg). The *C~max~* of prototype drug was 12.3±3.3 ng/mL and the average half-life was 4.94±2.53 h. At 36 h after administration, no drug was detected. The *C~max~* of wogonin after enzymolysis was significantly increased (156.5±40.9) ng/mL. The average half-life was also prolonged to (9.1±5.2) h. The individual time points after administration for 36 h were detected. Therefore, we deduced that the low bioavailability of wogonin might be caused by its low solubility associated with the fast binding with glucuronic acid *in vivo*. For most of the drugs, the phase II metabolites were not active *in vivo*. There were also several of the phase II drug metabolite activities that were stronger than the prototype drug. For example, the activity of the new cholesterol absorption inhibitor, ezetimibe, and morphine glucose acid conjugates was much stronger than the prototype \[[@b38-medscimonit-22-3737]\].

Conclusions
===========

The solvent method was successful using PVP K30 carrier for preparing SDs of wogonin. The solid state studies confirmed that solid dispersion of wogonin with carriers can decrease crystalline form of the drug or increase amorphousness of the drug, which can increase in the dissolution rate of wogonin from solid dispersion formulations. Further study indicates that low bioavailability of wogonin might be caused by its low solubility and associated with the fast binding with glucuronic acid *in vivo*. Research on the pharmacologic activity of wogonin glucuronic acid has important significance to the research and development of the drug.

The authors thank the staff of the Pharmacokinetics Department of Hefei Con-source Medicine Technology Co., Ltd., Anhui, China for their kind help during the study.

**Source of support:** This research supported by the Foundation of Natural Science of Anhui Province, China KJ2014A155 and the Foundation of Natural Science of Bengbu Medical College of Anhui Province, BYKY1409ZD. Project was also founded by the Natural Science Foundation gxfxZD2016148

![X- ray diffraction (**A**) wogonin; (**B**) PVP K30 wogonin crude material; (**C**) Wogonin PVP K30 physical mixture (1:5); (**D**) Wogonin-PVP K30 solid dispersion (1:5).](medscimonit-22-3737-g001){#f1-medscimonit-22-3737}

![Differential X-ray diffraction (**A**) PVP K30; (**B**) Wogonin crude material; (**C**) Physical mixture; (**D**) Solid dispersion, wogonin-PVP K30 (1:5).](medscimonit-22-3737-g002){#f2-medscimonit-22-3737}

![Concentration-time curves of different forms of intravenous administration.](medscimonit-22-3737-g003){#f3-medscimonit-22-3737}

![Concentration-time curves of different forms of gastric administration (crude drug and solid dispersion).](medscimonit-22-3737-g004){#f4-medscimonit-22-3737}

![Beagles were administrated wogonin solution (5 mg/kg) via the intragastric route. Concentration-time curves of free wogonin and its main metabolite, wogonin7-β-D-glucuronic (W-7-G) acid. Plasma concentrations of W-7-G in dogs are expressed as wogonin equivalents.](medscimonit-22-3737-g005){#f5-medscimonit-22-3737}

![Chemical structure of wogonin.](medscimonit-22-3737-g006){#f6-medscimonit-22-3737}

###### 

Comparison of statistical moment parameters of pharmacokinetics of different routes of administration of Wogonin to Beagles.

  Parameters                   i.v. (5 mg/kg)   i.g. native drug (15 mg/kg)                                         i.g. SDs (5 mg/kg)
  ---------------------------- ---------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  *AUC~(0-t)~* ug/L\*h         629.7±111.8      7.1±2.0[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}          21.0±3.2[a](#tfn2-medscimonit-22-3737){ref-type="table-fn"}[d](#tfn6-medscimonit-22-3737){ref-type="table-fn"}
  *AUC~(0-~*~∞~*~)~* ug/L\*h   631.9±112.8      10.8±5.0[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}         21.9±4.6[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}[c](#tfn5-medscimonit-22-3737){ref-type="table-fn"}
  *t~1/2z~* h                  5.9±6.9          10.1±8.9[a](#tfn2-medscimonit-22-3737){ref-type="table-fn"}         5.1±2.6[c](#tfn5-medscimonit-22-3737){ref-type="table-fn"}
  *t~max~* h                   \--±\--          0.7±0.3[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}          0.3±0.2[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}[d](#tfn6-medscimonit-22-3737){ref-type="table-fn"}
  *C~max~* ug/L                6838.7±1322.1    2.5±1.1[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}          7.9±3.3[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}[d](#tfn6-medscimonit-22-3737){ref-type="table-fn"}
  *CLz* L/h/kg                 8.1±1.5          1681.8±830.2[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}     844.5±507.1[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}[d](#tfn6-medscimonit-22-3737){ref-type="table-fn"}
  *Vz* ug/L                    67.9±73.4        18266.4±9922.5[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}   4975.5±1898.9[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}[d](#tfn6-medscimonit-22-3737){ref-type="table-fn"}
  *MRT~(0-t)~* h               0.12±0.03        3.6±0.2[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}          5.3±3.0[b](#tfn3-medscimonit-22-3737){ref-type="table-fn"}[d](#tfn6-medscimonit-22-3737){ref-type="table-fn"}

Compared with the iv group

*p*\<0.05

*p*\<0.01;

Compared with the ig group

*p*\<0.05

*p*\<0.01.

###### 

Bioavailability of different routes of administration of Wogonin to beagles.

  Number   i.v. (5 mg/kg)   i.g.~native\ drug~ (15 mg/kg)   i.g.~solid\ dispersions~ (5 mg/kg)   AB/%   RB/%   
  -------- ---------------- ------------------------------- ------------------------------------ ------ ------ --------
  No1      479.6            16.7                            31.8                                 1.2    6.6    571.3
  No2      748.5            7.4                             9.4                                  0.3    1.3    381.1
  No3      698.0            9.5                             17.0                                 0.5    2.4    536.8
  No4      743.1            15.2                            51.2                                 0.7    6.9    1010.5
  No5      561.6            5.1                             15.3                                 0.3    2.7    900.0
  Mean     646.2            10.8                            24.9                                 0.6    4.0    679.9
  sd       119.8            5.0                             16.8                                 0.4    2.6    264.3

Dog number 6 had vomiting after the administration of crude drug, which caused an inaccurate dosage of medication. The data of this dog was not included in the calculation of the bioavailability.

###### 

Statistical moment parameters of pharmacokinetics of Wogonin gastric administration to beagles (5 mg/kg; calculation of the free Wogonin and total Wogonin after enzymolysis, respectively).

  Parameters           Free Wogonin    Total Wogonin
  -------------------- --------------- ---------------
  AUC~(0-t)~ ug/L\*h   16.2±6.0        449.2±165.4
  AUC~(0-∞)~ ug/L\*h   17.8±7.4        554.8±371.4
  t~1/2z~ h            4.94±2.53       9.1±5.2
  T~max~ h             0.35±0.21       0.51±0.13
  C~max~ ug/L          12.3±3.3        156.5±40.9
  CLz L/h/kg           969.8±385.4     11.5±4.8
  Vz ug/L              6168.7±2013.6   130.4±40.1
  MRT~(0-t)~ h         3.39±1.25       8.38±3.14
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